Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research? All these questions, and more, will be answered by our scientific experts.
Amanda Finan, Ph.D., Head of R&D IHC, Cerba Research
Amanda Finan received her PhD in Cell Biology from Case Western Reserve University (Cleveland, OH, USA) studying cardiac gene therapy and stem cell biology at the Cleveland Clinic. She then transferred to France with a Marie Curie post-doctoral fellow to continue her research in cardiac regeneration in an INSERM laboratory in Montpellier. Amanda joined the R&D team focused on IHC at Cerba Research in 2018 and at the beginning of 2020 was promoted to Manager of IHC R&D. Amanda has extensive experience in physiology with a particular focus on immunohistochemistry and imaging.Message Presenter
Nithianandan Selliah, Ph.D., Global Head of Flow Cytometry, Cerba Research
Nithianandan Selliah obtained his PhD in Immunology, and started to work on HIV research. After more than 10 years of HIV researh, he joined a biotech company to work on biomarker discovery for autoimmune diseases. His interest in Flow cytometry at the biotech company led him to join a CRO to work on assay development and validation in Flow Cytometry for clinical trials. In 2019 he joined Cerba Research to continue to work on Flow Cytometry within clinical trials, and take on new challenges to build the best Flow Cytometry service.Message Presenter
Raouf Ben Abdelali, MD Ph.D., Head of the Hematology and Oncology Division, Cerba Laboratory
Raouf Ben Abdelali is an MD who graduated in medical cancer genetics in 2004. He obtained a PhD in Cellular and Molecular Biology, from the Doctoral School of Cancerology, Biology, Medicine and Health of the University of Paris in 2011. He was a post-doctoral fellow at the Cancer Research Institute of Lille. Abdelali joined Cerba in 2016 as a clinical pathologist in molecular Oncology and currently he is the Head of the Hematology and Oncology Division. Abdelali has extensive experience in cancer genetics with a focus on NGS technology.Message Presenter
Who Should Attend?
- Translational Medicine
- Clinical Operation Leaders
- Research and Early Clinical Development
- Biomarker & Experimental Medicine Leaders
What You Will Learn
In this webinar, speakers will discuss:
- Several detailed case studies: flow cytometry vs immunohistochemistry, Tumor Mutation Burden (TMB) and biomarker strategies
- The differences between Flow cytometry and Immunohistochemistry technologies and how complementary they can be
- The importance to identify biomarkers as of the start of preclinical research to identify the perfect Companion Diagnostic
Headquartered in Ghent, Belgium, Cerba Research is a Global Central & Specialist Laboratory.
Our footprint includes 6 harmonised central lab locations in Ghent, New York, Johannesburg, Shanghai, Taipei & Sydney.
Complimentary to these central labs, our network of Cerba specialty labs support our core therapy expertise in three distinct areas – Oncology, Liver Indications & Infectious Disease. APH, Flow Cytometry (16 colours globally) Genomics, Metabolomics, Microbiology + Virology and Molecular Biology permit our clients to discern and select correct instruments, appropriate sensitivities / detection and techniques for true full service delivery.
Worthy of note too is our unique presence in Africa. Complimentary to our Central Lab operation in Johannesburg, Cerba has the largest network of Labs, Staff Pathologists and supporting Logistics in Africa.
From preclinical transition to the clinic, and on to commercialisation, supporting emerging and established biotechs through to large global pharma clients, we are known and proud of our close partnering, higher frequency of contact and all round availability at your demand.
Our subject matter experts enjoy open collaboration at the pace our clients require to optimise their therapeutic development and draw those pivotal insights earlier. We partner with these clients to speed up their research and development whether it be in the area of discussing, agreeing and then delivery of specialized custom assays and panels, assay transfer, or perhaps overcoming operational peculiarities baked in to studies by way of challenges regarding stability of samples for testing. Every synopsis, protocol and study is unique and new challenges arise time after time. We are adept at meeting and overcoming those challenges and enjoying long standing and fruitful relationships with our sponsors.
We are ISO 15189 accredited, CAP CLIA accredited with no deficiencies cited to date, and with significant capabilities for testing under BSL3.
Cerba Research is the pharmaceutical development arm of Cerba Healthcare. Cerba Healthcare is Headquartered in Paris, France and employs >7,000 staff, including over 130 staff pathologists and conducting 40 million tests annually.